Review Suggests PEG-IFN Therapy for Relapsing-Remitting Multiple Sclerosis Significantly Reduces Relapse Rates

A study recently published in the journal PLoS One compared the use of a specific treatment based on interferon beta-1a with other approved injectable therapies in patients with relapsing-remitting multiple sclerosis (RRMS). The study is entitled “A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis” and was conducted by an international research team led by researchers at Tolley Health Economics Ltd. in the United Kingdom and Biogen Idec Inc.in the United States.
Read More